Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/120604 |
Resumo: | OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size. |
id |
USP-19_7221c296f9bfadbc6a0459b1b6f0e7ce |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/120604 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2016-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/12060410.6061/clinics/2016(08)05Clinics; Vol. 71 No. 8 (2016); 435-439Clinics; v. 71 n. 8 (2016); 435-439Clinics; Vol. 71 Núm. 8 (2016); 435-4391980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/120604/117678Copyright (c) 2016 Clinicsinfo:eu-repo/semantics/openAccessShiozaki, Afonso A.Senra, TiagoMorikawa, Aleksandra T.Deus, Débora F.Paladino-Filho, Antonio T.Pinto, Ibraim M.F.Maranhão, Raul C.2016-09-12T18:51:49Zoai:revistas.usp.br:article/120604Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2016-09-12T18:51:49Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
title |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
spellingShingle |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles Shiozaki, Afonso A. |
title_short |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
title_full |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
title_fullStr |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
title_full_unstemmed |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
title_sort |
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles |
author |
Shiozaki, Afonso A. |
author_facet |
Shiozaki, Afonso A. Senra, Tiago Morikawa, Aleksandra T. Deus, Débora F. Paladino-Filho, Antonio T. Pinto, Ibraim M.F. Maranhão, Raul C. |
author_role |
author |
author2 |
Senra, Tiago Morikawa, Aleksandra T. Deus, Débora F. Paladino-Filho, Antonio T. Pinto, Ibraim M.F. Maranhão, Raul C. |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Shiozaki, Afonso A. Senra, Tiago Morikawa, Aleksandra T. Deus, Débora F. Paladino-Filho, Antonio T. Pinto, Ibraim M.F. Maranhão, Raul C. |
description |
OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-08-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/120604 10.6061/clinics/2016(08)05 |
url |
https://www.revistas.usp.br/clinics/article/view/120604 |
identifier_str_mv |
10.6061/clinics/2016(08)05 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/120604/117678 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2016 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2016 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 71 No. 8 (2016); 435-439 Clinics; v. 71 n. 8 (2016); 435-439 Clinics; Vol. 71 Núm. 8 (2016); 435-439 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222762661314560 |